Dexlansoprazole
Brand name: Dexlansoprazole Dr
Rank #162 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$98.7M
Total Cost
275,116
Total Claims
$98.7M
Total Cost
9,884
Prescribers
$359
Cost per Claim
26,262
Beneficiaries
418,402
30-Day Fills
$9,985
Avg Cost/Provider
28
Avg Claims/Provider
Share of Medicare Part D Spending
0.04%
of total Medicare Part D spending
$98.7M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $98.7M total
Top Prescribers of Dexlansoprazole
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Jaesoo Pak | Internal Medicine | Cerritos, CA | 703 | $286K |
| 2 | Alexander Brodsky | Gastroenterology | Brooklyn, NY | 1,057 | $272K |
| 3 | Homayoun Sharim | Internal Medicine | Beverly Hills, CA | 785 | $266K |
| 4 | Shang Wu | Gastroenterology | Hacienda Heights, CA | 483 | $243K |
| 5 | Arutyun Topsakalyan | General Practice | Glendale, CA | 978 | $243K |
| 6 | Xiangsheng Zheng | Internal Medicine | Birmingham, AL | 936 | $233K |
| 7 | Sang Baik | Internal Medicine | Los Angeles, CA | 548 | $230K |
| 8 | Kelvin Mai | Internal Medicine | Santa Ana, CA | 599 | $229K |
| 9 | Gopal Narasimhan | Internal Medicine | New York, NY | 515 | $226K |
| 10 | Herach Yadegarian | General Practice | Glendale, CA | 599 | $222K |
| 11 | Jiho Choi | Family Practice | Annandale, VA | 420 | $211K |
| 12 | Gary Reznik | Cardiology | Los Angeles, CA | 854 | $203K |
| 13 | Afshine Emrani | Cardiology | Tarzana, CA | 547 | $199K |
| 14 | Aleksandr Zasypkin | Internal Medicine | Brooklyn, NY | 764 | $188K |
| 15 | Thuan Vo | Internal Medicine | Westminster, CA | 393 | $187K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 159 | Tocilizumab (Actemra) | $99.5M | 24,891 |
| 160 | Omalizumab (Xolair) | $98.9M | 30,451 |
| 161 | Brimonidine Tartrate (Alphagan P) | $98.8M | 988,570 |
| 162 | Dexlansoprazole (Dexlansoprazole Dr) | $98.7M | 275,116 |
| 163 | Interferon Beta-1a (Avonex) | $98.3M | 11,314 |
| 164 | Guselkumab (Tremfya) | $97.1M | 7,102 |
| 165 | Levetiracetam (Levetiracetam) | $96.1M | 1,723,736 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology